Comparison
While Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880, Thymosin Beta-4 promotes wound healing, angiogenesis, and tissue regeneration in preclinical models via effects on cytoskeleton dynamics, cell migration, and anti-apoptotic pathways25579.
While Liraglutide works as a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880, Thymosin Beta-4 is an endogenous 43-amino-acid actin-sequestering peptide that maintains a pool of G-actin monomers and regulates actin polymerization, thereby influencing cell migration, proliferation, and differentiation25579.
Liraglutide is 31 amino acids long, whereas Thymosin Beta-4 is longer as it has a length of 43 amino acids. Liraglutide is made up of a sequence of sequence data not available in the current dataset. Thymosin Beta-4 is made up of a sequence of Serine, Aspartic acid, Lysine, Proline, Aspartic acid, Methionine, Alanine, Glutamic acid, Isoleucine, Glutamic acid, Lysine, Phenylalanine, Aspartic acid, Lysine, Serine, Lysine, Lysine, Proline, Aspartic acid, Methionine, Alanine, Glutamic acid, Glutamic acid, Lysine, Phenylalanine, Aspartic acid, Lysine, Lysine, Glutamic acid, Lysine, Lysine, Glutamic acid, Glutamic acid, Alanine, Glutamic acid, Asparagine, Glutamic acid, Glutamic acid, Lysine, Glutamic acid, Serine.
Liraglutide
GCG
Thymosin Beta-4
TMSB4X